Precision Reimagined: CRISPR and Multiomics Transform Systemic Lupus Erythematosus Diagnosis and Therapy
Authors:
- 23 April 2025
- journal article
- review article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (4) , e70189
Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with diverse clinical manifestations and unpredictable progression, posing significant challenges to accurate diagnosis and effective treatment. Traditional biomarkers and treatments often fail to address the disease's molecular and clinical heterogeneity. Recent advancements in CRISPR gene‐editing technology and multiomics approaches offer transformative opportunities for personalized SLE care by unraveling its underlying molecular complexity and enabling precise therapeutic interventions. CRISPR technology allows targeted editing of SLE‐associated genetic mutations, addressing disease drivers directly, while multiomics—including genomics, transcriptomics, and proteomics—provides insights into dysregulated immune networks, identifying biomarkers and therapeutic targets. Integrating these approaches can refine patient stratification and enhance the precision of treatments. Artificial intelligence (AI) complements these technologies by synthesizing high‐dimensional data, enabling personalized treatment plans, predicting disease trajectories, and optimizing therapeutic strategies. However, the integration of CRISPR and multiomics in clinical settings raises challenges, including technical limitations, ethical concerns, and economic barriers. Emerging clinical trials and case studies demonstrate the potential of these innovations to personalize care and improve outcomes. Nonetheless, the transition from experimental research to routine clinical application requires robust regulatory frameworks and strategies to address these challenges. This review aims to explore the potential of CRISPR and multiomics technologies to revolutionize SLE diagnosis and therapy, emphasizing their integration with AI to advance personalized care. By addressing existing barriers, the review envisions a future where precision medicine transforms SLE management, paving the way for individualized, patient‐centered autoimmune therapy.Keywords
This publication has 69 references indexed in Scilit:
- Integration of multi-omics analysis reveals metabolic alterations of B lymphocytes in systemic lupus erythematosusClinical Immunology, 2024
- A Multilayered Post–Genome‐Wide Association Study Analysis Pipeline Defines Functional Variants and Target Genes for Systemic Lupus ErythematosusArthritis & Rheumatology, 2024
- Three‐Dimensional Chromosomal Landscape Revealing miR‐146a Dysfunctional Enhancer in Lupus and Establishing a CRISPR‐Mediated Approach to Inhibit the Interferon PathwayArthritis & Rheumatology, 2023
- Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapiesCurrent Opinion in Biotechnology, 2022
- Distinct transcriptome architectures underlying lupus establishment and exacerbationCell, 2022
- The immunomodulatory effects of mesenchymal stromal cell‐based therapy in human and animal models of systemic lupus erythematosusIUBMB Life, 2020
- Systemic lupus erythematosus: Diagnosis and clinical managementJournal of Autoimmunity, 2019
- A CRISPR–dCas Toolbox for Genetic Engineering and Synthetic BiologyJournal of Molecular Biology, 2019
- Key genes and functional coexpression modules involved in the pathogenesis of systemic lupus erythematosusJournal of Cellular Physiology, 2018
- Genetic susceptibility to SLE: Recent progress from GWASJournal of Autoimmunity, 2013